Aileron Therapeutics, Inc. (ALRN)

$ 0.5891
+0.02 (+3.95%)
Neutral
Symbol ALRN
Price $ 0.5891
Beta 2.552
Volume Avg. 0.51M
Market Cap 0.053B
Shares () -
52 Week Range 0.55-2.33
1y Target Est -
DCF Unlevered ALRN DCF ->
DCF Levered ALRN LDCF ->
ROE -54.19% Strong Sell
ROA -44.48% Strong Sell
Operating Margin -
Debt / Equity 9.30% Neutral
P/E -
P/B 1.06 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ALRN news


Dr. Manuel Aivado
Healthcare
Biotechnology
Nasdaq Global Market

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.